← Research ProtocolsThymosin Alpha-1
STUDIED EXPOSURE MAP / 2020
Thymosin Alpha-1
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN LITERATURE / REVIEWED EXPOSURE RANGEREVIEW OF PUBLISHED LITERATURESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
0.8–6.4 mg
single-dose range reported in review
1.6–16 mg
multiple-dose range reported over 5–7 days
Context: This is a review-level exposure summary, not one standardized trial protocol. Disease context, schedule and concomitant therapy varied across studies.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / REVIEW OF PUBLISHED LITERATURE
Thymosin alpha 1: A comprehensive review of the literature
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2020
01 / DESIGNReview summarizing clinical and experimental literature
02 / POPULATION / MODELMultiple disease contexts across published studies
03 / ROUTEPrimarily subcutaneous in the reviewed clinical literature
04 / TIMEFRAMEVaried by study
05 / PRIMARY QUESTIONVaried immune and clinical endpoints
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Immune-signalling research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.